163 results about "Lungs tissues" patented technology

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

Application of a high-purity inonotus obliquus polysaccharide component belongs to the technical field of biological medicine, and the high-purity inonotus obliquus polysaccharide component plays a role in preventing and treating by inhibiting autophagy of lung tissue cells and depending on an lncRNA Rmst pathway, and can reduce the number of autophagosomes in lung tissues and the level of conversion from LC3-I to LC3-II; according to the method, the sugar content of IOP can be remarkably increased compared with crude polysaccharide, the protein content is remarkably reduced, four active components with specific molecular weights are obtained through separation, the molecular weight ranges are definite (IOP-g1gt, IOP-g2gt, IOP-g3gt and IOP-g4), and the requirements of medicine research and development for controllable purity and definite components are met.

Methods and systems are described for a high-level approach to organ generation by self-assembly using bioprinting, overcoming longstanding challenges in replicating the intricate architecture and function of complex organs. In some embodiments, these methods are used to produce lung tissues and microtissues, demonstrating how mini-lung constructs can be produced on a small scale through specialized processes and media. In such embodiments, methods and systems for generating bioprinted lung tissues and microtissues are provided, as are tissues made by such methods. The tissues find use in implantation, drug discovery, personalized medicine, and other applications. Methods for the large-scale manufacturing of lung epithelial stem cells are also provided.

The application relates to a fusion protein and application thereof in the field of biotechnology. A polypeptide fragment for specifically recognizing a single-molecule phospholipid membrane and a polypeptide fragment for specifically recognizing a tissue or a cell are connected to form a fusion protein which can be specifically combined to a fat body surface in a non-covalent manner, so that precise targeting of the fat body is realized. The fat body targeting peptide segment can be widely used in the fields of precise drug delivery and vaccine preparation, so as to be used for treating diseases such as cancer, infectious diseases and metabolic diseases. Lung tissues and breast cancer cells are taken as target points, and good targeting of the fat body is realized.

The invention discloses an application of isothunberine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating asthma diseases. It is found that in an OVA-induced mouse asthma model, the isothunberine significantly reduces airway resistance excited by acetylcholine, improves inflammatory cell infiltration and airway mucus high secretion of asthma model mouse lung tissue, reduces the levels of lgE and OVA-lgE in serum and related inflammatory factors in alveolar lavage fluid, and has the effect of preventing and treating asthma. Therefore, the effect of treating asthma is achieved. Therefore, the isothunberine has the potential of preventing or treating the asthma, provides a new treatment mode for the treatment of the asthma, and has a wide application prospect.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The invention discloses an application of a compound fresh bamboo juice in a guinea pig asthma model, and relates to the field of medicines, a Hartley albino guinea pig is adopted to construct an OVA induced asthma model, and the model is verified to be successfully constructed through evaluation indexes; evaluating the efficacy of the successfully constructed guinea pig asthma model by using different doses of compound fresh bamboo juice, and evaluating the efficacy of the guinea pig asthma model by scoring guinea pig capsaicin stimulation cough inducing times, alveolar lavage fluid leukocyte number, inflammatory factor content, lung tissue hydroxyproline content and behavioral signs. And evaluating the treatment effect of the compound fresh bamboo juice through Western blot detection, lung histopathology and immunofluorescence staining indexes. In a guinea pig asthma model, high-dose and medium-dose groups of the compound fresh bamboo juice can be used for remarkably reducing the number of cough, reducing the number of white blood cells in alveolar lavage fluid and the level of inflammatory factors and inhibiting pulmonary fibrosis, and a good treatment effect is shown. The results provide powerful support for potential application of the compound fresh bamboo juice in asthma treatment.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

The invention discloses a preparation method of a pyridopyrimidine compound and application of the pyridopyrimidine compound in preparation of an asthma medicine. The pyridopyrimidine compound provided by the invention is applied to preparation of medicines for preventing / treating asthma, DPPO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the DPPO can obviously inhibit attack of asthma and secretion of related inflammatory factors such as IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17A, has a relaxation effect on tracheal smooth muscles, has the effects of resisting angiogenesis, airway remodeling and inflammation, and achieves the effect of treating asthma. In addition, current researches show that the asthma pathogenesis is very complex, DPPO can obviously improve pathological changes of mouse lung tissues sensitized by house dust mite extract (HDM) and toluene diisocynate (TDI), and the DPPO has certain universality and can be speculated to have huge application potential in research and development of drugs for treating various asthma.

This invention belongs to the field of biomedical technology and discloses the application of KDELR3 inhibitors in the preparation of drugs for the prevention and / or treatment of individual fibrotic diseases. In a wild-type mouse model of pulmonary fibrosis, compared with the control group receiving intratracheal injection of Scr siRNA, intratracheal injection of KDELR3 siRNA significantly reduced the degree of fibrosis in the mouse lung tissue. KDELR3 inhibition significantly reduced collagen deposition and improved lung tissue structural damage. Further mechanistic studies showed that KDELR3 inhibitors can inhibit the differentiation of fibroblasts into myofibroblasts, thereby reducing the production of fibrosis-related extracellular matrix. These results indicate that KDELR3 is a key molecule regulating the occurrence and development of fibrosis, and drugs that can inhibit KDELR3 expression or activity can be used to prevent and treat various fibrotic diseases, including pulmonary fibrosis, laying the foundation for the development of novel drugs that are effective and safe in treating fibrotic diseases.

Systems and methods are provided for delivering a therapeutic treatment to a target population of cells (including, but not limited to, tumors, eyeballs, pancreatic tissue, liver tissue, and lung tissue) in a subject. The system includes an injectable aqueous solution in a vial enclosed with a septum. The solution comprises particles containing a therapeutic agent and having a coating surrounding the therapeutic agent, the coating comprising chitosan to provide controlled release of the agent from the particles. The solution also comprises a chitosan polymer in the form of a polymer gel matrix, further providing controlled release of the particles from the aqueous gel environment. There is also provided a method of making a freeze-dried powder placed in a vial containing a chitosan polymer and chitosan-coated particles, the powder when mixed with water forming the above injectable aqueous solution with particles and chitosan gel.

The application relates to the field of biomedical technology, and discloses an application of a GCA-NAb monoclonal antibody in the preparation of a drug for preventing and / or treating pulmonary fibrosis. The application mainly relates to the application of an amino acid sequence of the GCA-NAb monoclonal antibody as shown in SEQ ID No. 2 in the preparation of the drug for preventing and / or treating pulmonary fibrosis. The GCA-NAb monoclonal antibody can significantly improve pulmonary fibrosis, and can prolong the survival cycle of a mouse model, reduce the proportion of TH17 cells in lung tissues, and slow down the progress of pulmonary fibrosis. In addition, the antibody can directly affect the transformation of fibroblasts, inhibit the transformation of the fibroblasts into myofibroblasts, and thus reduce the fibrosis. The GCA-NAb monoclonal antibody has the characteristics of high efficiency and safety.

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.

The invention discloses procyanidine B2G2 from purple sweet potato Ningzi No.4 and application thereof, and belongs to the technical field of biological medicine, the molecular formula of the procyanidine B2G2 is C44H34O20, and the molecular weight of the procyanidine B2G2 is 882.736 Da. The procyanidine B2G2 remarkably relieves acute lung injury ALI by inhibiting inflammatory response and ferroptosis induced by klebsiella pneumoniae KP; experiments show that B2G2 can reduce the lung tissue injury score, the lung wet / dry ratio, the expression of inflammatory factors TNF-alpha, IL-6 and IL-1beta and the bacterial load, and up-regulate the expression of ferroptosis related proteins GPX4, SLC7A11 and HO-1; in addition, B2G2 is non-toxic to liver and kidney functions and has good safety, and the application provides a new drug candidate scheme for preparation of drugs for treating acute lung injury.

The present application relates to the technical field of content detection, in particular to a method for rapidly detecting the content of hydroxyproline in mouse lung tissue, which comprises the following steps: obtaining the original sampling spectrum of the lung tissue of the mouse to be detected at different preset sampling points, and obtaining a non-lung tissue interference characteristic base matrix containing whole blood characteristics and cartilage characteristics; setting an orthogonal filter operator and determining a lung interstitium characteristic spectrum vector; constructing a reference spectrum vector and determining a relative spectral response factor; constructing a spectral minimum spanning tree and determining a signal contribution weight based on the spectral minimum spanning tree and the relative spectral response factor; generating a whole lung fibrosis synthetic spectrum according to the signal contribution weight and the lung interstitium characteristic spectrum vector, and detecting the content of hydroxyproline based on the whole lung fibrosis synthetic spectrum. The present application considers the non-lung tissue interference containing whole blood characteristics and cartilage characteristics when detecting the content of hydroxyproline, which improves the rationality of the detection of the content of hydroxyproline to a certain extent.

The application discloses a new use of a BET inhibitor YD-851 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis. The application finds that YD-851 can inhibit the expression of BRD4 and fibrosis-related markers in pulmonary fibrosis tissues, reduce the structural damage of bleomycin-induced mouse lung tissues, inflammatory cell infiltration and fibrosis pathological changes, and improve lung function damage. Experimental results show that YD-851 can reduce the pulmonary fibrosis score, inflammation score and area ratio of consolidation, improve the lung imaging abnormalities, and down-regulate the expression of fibrosis-related genes such as Col1a1, Fn1 and Acta2. It is shown that YD-851 has the effect of treating pulmonary fibrosis, and can be used for preparing a drug for treating pulmonary fibrosis, and a new use of YD-851 is developed.

The invention relates to the technical field of biological medicines, in particular to application of palmitic acid and a preparation thereof in preparation of medicines for preventing and treating acute exacerbation of chronic obstructive pulmonary diseases. The invention provides application of palmitic acid and a preparation thereof in preparation of a medicine for preventing and treating acute exacerbation of chronic obstructive pulmonary disease. Research finds that supplement of palmitic acid in an acute infection period can improve IFITM3 protein expression of alveolar epithelial cells and further promote downstream secretion of TGF beta by up-regulating the expression level of anti-inflammatory cytokines, so that lung tissue inflammation regression and tissue repair are promoted, and the lung function of patients with chronic obstructive pulmonary diseases is improved.

The present disclosure relates generally to lipid nanoparticles (LNPs) and compositions comprising the same, and their use for delivering agents, such as nucleic acid-based therapeutic agents, particularly to transfected resistant cells and / or lung tissue.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

This invention generally relates to a technique for degrading systemic toxins in vivo by enhancing the metabolic function of the lungs. Such a technique involves introducing a composition into the lung tissue of a subject, the composition comprising at least one enzyme known to enzymatically break down at least one toxin systemically present in the subject's body. The provided technique enables the lungs to act as a modulated metabolic organ, thereby promoting the removal of toxins from the systemic circulation of a subject, such as a subject suffering from a condition leading to the accumulation of toxins or endogenous metabolites, or a subject who has ingested toxic substances.

This invention relates to the field of traditional Chinese medicine technology, and more particularly to the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of lung injury. The traditional Chinese medicine composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that this traditional Chinese medicine composition can significantly reduce the level of the inflammatory factor TNF-α, decrease the lung index, and alleviate pathological damage to lung tissue, and can be used for the prevention and treatment of lung injury.

Tissue-specific progenitor cells representing the endoderm, ectoderm, and mesoderm lineages are generated from pluripotent sources. Progenitor cell generation is accomplished by contacting pluripotent stem cells with tissue-specific exosomes, microRNAs, proteins, and peptides, obtained by stressing the tissue under in vitro conditions. In vitro-generated tissue organoids are used as a source of "differentiation factors" for generating individualized progenitor cells. For example, to generate lung progenitor cells, allogeneic stem cells are implanted into decellularized cadaveric lung tissue to form lung structures, which are then exposed to various cellular stressors and conditioned media to differentiate the pluripotent stem cells into progenitor cells. Extracellular matrix can be obtained from decellularized structures seeded with regenerating cells and used to generate organoids, which are then subjected to stress to produce differentiation factors.

The invention belongs to the technical field of biomedicine, and discloses an antibody for evaluating the curative effect of infantile pneumonia asthma and application of the antibody. The heavy chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 2-4, the light chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 6-8, the dissociation constant of the monoclonal antibody and an IL-5R antigen reaches 2.435 * 10 <-1 > / L, and the affinity is high. The antibody can accurately evaluate the curative effect of infantile pneumonia and asthma by detecting the lung function, the ratio of eosinophilic granulocytes in bronchoalveolar lavage fluid and lung tissue inflammation, can also significantly improve airway obstruction and inflammation of asthma model mice, has an effect superior to that of dexamethasone, solves the problems that existing curative effect evaluation is lack of specific tools and has large side effects of therapeutic drugs, and has good clinical application prospects. And a new scheme is provided for curative effect evaluation and adjuvant therapy of infantile pneumonia asthma.

The invention discloses application of CD177 in diagnosis and treatment of inflammatory lung injury. The research determines that the neutrophil surface molecule CD177 is obviously and abnormally increased in a patient with acute respiratory distress syndrome (ARDS) and is a reliable immune target for diagnosing lung injury; animal experiments prove that the CD177 has a key therapeutic effect in acute lung injury: the deficiency of the CD177 can obviously inhibit excessive infiltration of neutrophil in lung tissues, and the acute lung injury of mice is relieved.

Provided herein are devices, systems, and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, devices, systems, and methods are provided for delivering energy to difficult to access tissue regions (e.g. central or peripheral lung tissues), and / or reducing the amount of undesired heat given off during energy delivery.

The application discloses a bovine parainfluenza virus 3A and 3C type polyepitope antigen peptide, a complex thereof and application. The polyepitope antigen peptides BPMEV-3A and BPMEV-3C have amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 respectively, and are connected by screening CTL epitopes, HTL epitopes and B cell epitopes from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immunization tests show that the antigen peptide and the complex thereof can effectively stimulate the body to produce specific IgG antibodies and neutralizing antibodies, induce Th1 type cellular immune response, and effectively eliminate viruses and reduce lung tissue lesions, and show good immunogenicity and protection effect. The application provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The invention relates to the technical field of medicines, in particular to a zinc ion polypeptide compound immunologic adjuvant as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing polypeptide, a PBS buffer solution, new coronavirus S protein, a CpG ODN immune activator and zinc ions, and standing to obtain the zinc ion polypeptide compound immunologic adjuvant. A dual-adjuvant system mixed with CpG ODN shows excellent performance in activation of lung tissue immunity, and in the cellular immunity level, the response intensity of CD4 + T and CD8 + T cells is enhanced, and formation of related tissue resident memory T cell phenotypes is promoted; on the humoral immunity level, a Gel (Zn < 2 + >) and CpG ODN dual-adjuvant system obviously stimulates the increase of the number of B cells and the activation, and can effectively stimulate the secretion of a main antibody sIgA for mucosal immunity. On the whole, the dual adjuvants realize the synergistic enhancement of T cell (containing TRM) and B cell immunity.

The application discloses a Leuconostoc intestini and Lactococcus lactis composition and application, belongs to the field of microbial pharmacy, and relates to application of a Leuconostoc intestini and Lactococcus lactis composition to preparation of a drug for treating pulmonary fibrosis diseases; wherein the quantity of the Leuconostoc intestini and the Lactococcus lactis in the composition is equal in terms of colony forming units. Experimental results show that the Leuconostoc intestini and the Lactococcus lactis can effectively improve pulmonary fibrosis when being intervened alone or in combination. It is known to those skilled in the art that excessive deposition of collagen fibers is a core feature of pulmonary fibrosis diseases, and the Leuconostoc intestini and the Lactococcus lactis have a synergistic effect of inhibiting the content of lung tissue collagen in pulmonary fibrosis. Therefore, the Leuconostoc intestini and the Lactococcus lactis composition has a prospect of being developed into a drug for treating pulmonary fibrosis diseases (including idiopathic pulmonary fibrosis and secondary pulmonary fibrosis).

The invention discloses a polyclonal antibody for treating pulmonary infection as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method comprises the following steps: culturing pathogenic bacteria causing pulmonary infection by taking pig lung tissues as a culture medium, collecting the tissues, and homogenizing to obtain homogenate; performing antigen extraction and purification treatment on the homogenate, and performing inactivation treatment to obtain an inactivated antigen; immunizing a horse with the inactivated antigen, and collecting and separating to obtain serum; and carrying out antibody extraction and purification on the serum to obtain the polyclonal antibody. The prepared polyclonal antibody has the advantages of strong neutralization broad spectrum, high neutralization activity and good pulmonary infection treatment effect.